sarilumab - for COVID-19   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.10 [0.58, 2.10]< 121%2 studies (2/-)38.1 %highnot evaluable lowcrucial-
clinical improvement 1.77 [1.06, 2.96]> 10%2 studies (2/-)98.5 %highnot evaluable lowimportant-
death or ventilation 0.53 [0.30, 0.94]< 120%2 studies (2/-)98.5 %highnot evaluable lowimportant-
ventilation 0.27 [0.14, 0.55]< 10%2 studies (2/-)100.0 %highnot evaluable lowimportant-
off oxygenation 1.46 [0.79, 2.68]> 128%2 studies (2/-)88.7 %highnot evaluable lownon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

This meta-analysis covered 1 pathologies: 87,95,94,90,91,97 91